TABLE 1.
Parameters | cKP | HvKP | Hv‐CRKP or CR‐HvKP | References |
---|---|---|---|---|
Typical infections | Pneumonia, UTI, bacteremia | PLA; lung, neck and kidney abscesses; endophthalmitis; necrotizing fasciitis; meningitis; pneumonia; cellulitis; myositis; septic arthritis; osteomyelitis | Combined infections by cKP and HvKP | 19, 26, 27, 28, 29, 30, 31, 32, 33 |
Susceptible populations | Immunocompromised (diabetics, patients with malignancies or transplant, bedridden individuals) | Diabetics, otherwise healthy individuals | Combined populations | 19, 20, 28, 29, 34, 35, 36, 37 |
Serotypes | K1‐K79 | Mostly K1 and K2, seldom K5 and K57 | K64, K47, K20, K2 and K20 | 1, 28, 29, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 |
Siderophores (positive rates, %) | Enterobactin (100), yersiniabactin (17–46), salmochelin (2–4), aerobactin (6) | Enterobactin (100), yersiniabactin (90), salmochelin (>90), aerobactin (>93) | Enterobactin (100), yersiniabactin (90), salmochelin (40), aerobactin (>93) | 40, 51, 52, 53, 54, 55, 56 |
Geographical prevalence | Worldwide | Mostly the Asian Pacific Rim, the trend to the world | Mainly Asia, the trend to the world | 29, 30, 32, 38, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 |
Commonly acquired infection type | Primarily nosocomial | Community acquired | Often nosocomial and seldom community‐acquired | 29, 59, 77, 78, 79, 80 |
Drug‐resistance | Frequent (for example ESBLs and carbapenemase‐producing) | Rare except penicillin‐resistance | Carbapenemase‐producing | 9, 19, 28, 29, 81, 82 |
Abbreviations: cKP, classical Klebsiella pneumoniae; CR‐HvKP, carbapenem‐resistant hypervirulent Klebsiella pneumoniae; ESBLs, extended‐spectrum β‐lactamases; HvKP, hypervirulent Klebsiella pneumoniae; Hv‐CRKP, hypervirulent carbapenem‐resistant Klebsiella pneumoniae; PLA, pyogenic liver abscess; UTI, urinary tract infection ; PLA, pyogenic liver abscess.